Cargando…

A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients

In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that of immune priming to induce prompt and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Y, Maeda, Y, Shomura, H, Sasatomi, T, Takahashi, M, Une, Y, Kondo, M, Shinohara, T, Hida, N, Katagiri, K, Sato, K, Sato, M, Yamada, A, Yamana, H, Harada, M, Itoh, K, Todo, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409683/
https://www.ncbi.nlm.nih.gov/pubmed/15054451
http://dx.doi.org/10.1038/sj.bjc.6601711
_version_ 1782155832807391232
author Sato, Y
Maeda, Y
Shomura, H
Sasatomi, T
Takahashi, M
Une, Y
Kondo, M
Shinohara, T
Hida, N
Katagiri, K
Sato, K
Sato, M
Yamada, A
Yamana, H
Harada, M
Itoh, K
Todo, S
author_facet Sato, Y
Maeda, Y
Shomura, H
Sasatomi, T
Takahashi, M
Une, Y
Kondo, M
Shinohara, T
Hida, N
Katagiri, K
Sato, K
Sato, M
Yamada, A
Yamana, H
Harada, M
Itoh, K
Todo, S
author_sort Sato, Y
collection PubMed
description In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that of immune priming to induce prompt and strong immunity. In this study, 10 human histocompatibility leukocyte antigen-A24(+) patients with advanced colorectal carcinomas were treated with up to four peptides that had been positive for pre-vaccination measurement of peptide-specific CTL precursors in the circulation (CTL precursor-oriented peptide vaccine). No severe adverse effect was observed, although local pain and fever of grade I or II were observed. Post-vaccination peripheral blood mononuclear cells (PBMCs) from five patients demonstrated an increased peptide-specific immune response to the peptides. Increased CTL response to cancer cells was detected in post-vaccination PBMCs of five patients. Antipeptide immunoglobulin G became detectable in post-vaccination sera of seven patients. Three patients developed a positive delayed-type hypersensitivity response to at least one of the peptides administrated. One patient was found to have a partial response; another had a stable disease, sustained through 6 months. These results encourage further development of CTL precursor-oriented vaccine for colorectal cancer patients.
format Text
id pubmed-2409683
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24096832009-09-10 A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients Sato, Y Maeda, Y Shomura, H Sasatomi, T Takahashi, M Une, Y Kondo, M Shinohara, T Hida, N Katagiri, K Sato, K Sato, M Yamada, A Yamana, H Harada, M Itoh, K Todo, S Br J Cancer Clinical In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that of immune priming to induce prompt and strong immunity. In this study, 10 human histocompatibility leukocyte antigen-A24(+) patients with advanced colorectal carcinomas were treated with up to four peptides that had been positive for pre-vaccination measurement of peptide-specific CTL precursors in the circulation (CTL precursor-oriented peptide vaccine). No severe adverse effect was observed, although local pain and fever of grade I or II were observed. Post-vaccination peripheral blood mononuclear cells (PBMCs) from five patients demonstrated an increased peptide-specific immune response to the peptides. Increased CTL response to cancer cells was detected in post-vaccination PBMCs of five patients. Antipeptide immunoglobulin G became detectable in post-vaccination sera of seven patients. Three patients developed a positive delayed-type hypersensitivity response to at least one of the peptides administrated. One patient was found to have a partial response; another had a stable disease, sustained through 6 months. These results encourage further development of CTL precursor-oriented vaccine for colorectal cancer patients. Nature Publishing Group 2004-04-05 2004-03-02 /pmc/articles/PMC2409683/ /pubmed/15054451 http://dx.doi.org/10.1038/sj.bjc.6601711 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Sato, Y
Maeda, Y
Shomura, H
Sasatomi, T
Takahashi, M
Une, Y
Kondo, M
Shinohara, T
Hida, N
Katagiri, K
Sato, K
Sato, M
Yamada, A
Yamana, H
Harada, M
Itoh, K
Todo, S
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
title A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
title_full A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
title_fullStr A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
title_full_unstemmed A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
title_short A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
title_sort phase i trial of cytotoxic t-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409683/
https://www.ncbi.nlm.nih.gov/pubmed/15054451
http://dx.doi.org/10.1038/sj.bjc.6601711
work_keys_str_mv AT satoy aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT maeday aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT shomurah aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT sasatomit aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT takahashim aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT uney aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT kondom aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT shinoharat aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT hidan aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT katagirik aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT satok aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT satom aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT yamadaa aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT yamanah aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT haradam aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT itohk aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT todos aphaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT satoy phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT maeday phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT shomurah phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT sasatomit phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT takahashim phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT uney phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT kondom phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT shinoharat phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT hidan phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT katagirik phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT satok phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT satom phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT yamadaa phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT yamanah phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT haradam phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT itohk phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients
AT todos phaseitrialofcytotoxictlymphocyteprecursororientedpeptidevaccinesforcolorectalcarcinomapatients